ADVM
Adverum Biotechnologies Inc

5,093
Mkt Cap
$93.83M
Volume
335,643.00
52W High
$6.98
52W Low
$1.78
PE Ratio
-0.50
ADVM Fundamentals
Price
$4.19
Prev Close
$4.25
Open
$4.25
50D MA
$4.26
Beta
0.99
Avg. Volume
926,278.87
EPS (Annual)
-$6.62
P/B
-1.68
Rev/Employee
$6,451.61
Loading...
Loading...
News
all
press releases
Beyond GLP-1: Eli Lilly's Expanding Drug Portfolio Lifts Sales
LLY???s newest approvals and pipeline deals add fresh momentum to revenue growth as the company expands beyond its GLP-1 blockbusters.
Zacks·10h ago
News Placeholder
More News
News Placeholder
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to...
PR Newswire·22h ago
News Placeholder
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-HOUS, ADVM, HBAN, and COMP
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-HOUS, ADVM, HBAN, and COMP $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-HOUS...
PR Newswire·1d ago
News Placeholder
The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum
Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and post rising estimates.
Zacks·3d ago
News Placeholder
Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ
Eli Lilly's surging GLP-1 momentum and Johnson & Johnson's diversified strength set up a compelling 2025 showdown for investors weighing growth vs. stability.
Zacks·3d ago
News Placeholder
Adverum Biotechnologies, Inc. $ADVM is BML Capital Management LLC's 7th Largest Position
BML Capital Management LLC boosted its holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) by 11.5% during the second quarter, according to its most recent 13F filing with the...
MarketBeat·3d ago
News Placeholder
Adverum Biotechnologies (NASDAQ:ADVM) Announces Earnings Results, Misses Expectations By $0.23 EPS
Adverum Biotechnologies (NASDAQ:ADVM - Get Free Report) issued its earnings results on Wednesday. The biotechnology company reported ($2.03) EPS for the quarter, missing the consensus estimate of...
MarketBeat·7d ago
News Placeholder
Lilly Up 18% in a Month: Should You Buy, Sell or Hold the Stock?
Eli Lilly stock jumps 18% in a month as strong Q3 results, upgraded guidance and rising demand for Mounjaro and Zepbound fuel investor optimism.
Zacks·9d ago
News Placeholder
Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales
Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year sales and earnings outlook.
Zacks·21d ago
News Placeholder
HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR...
PR Newswire·24d ago

Latest ADVM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.